Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

2018/11/29 by Stergios A. Polyzos, Stergios A. Pοlyzos, Jannis Kountouras +2 · 1,242 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cirrhosis #Diabetes mellitus #Diet, Metabolism, and Disease #Disease #Endocrinology #Fatty liver #Gastroenterology #Internal medicine #Liraglutide #Liver Disease Diagnosis and Treatment #Liver disease #Medicine #Metabolism, Diabetes, and Cancer #Nonalcoholic fatty liver disease #Obesity #Orlistat #Pharmacotherapy #Phentermine #Rimonabant #Type 2 diabetes #Weight loss

paper · doi:10.1016/j.metabol.2018.11.014

published in Metabolism 92, 82-97 (Elsevier BV)

openalex publication_date 2018/11/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06

Citations

• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
• Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease

Cited by

• The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis
• Adiponectin and leptin in the diagnosis and therapy of NAFLD
• The Therapeutic Potential of Theobromine in Obesity: A Comprehensive Review
• Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
• Sarcopenia and MASLD: novel insights and the future
• Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease
• Global Impact of Obesity
• Non-invasive imaging diagnostic techniques in metabolic dysfunction-associated steatotic liver disease: a roadmap for clinicians
• Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. [europepmc]
• Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. [europepmc]
• Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. [europepmc]
• The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. [europepmc]
• NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. [europepmc]
• Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. [europepmc]
• NAFLD and liver transplantation: Disease burden, current management and future challenges. [europepmc]
• Immunological mechanisms and therapeutic targets of fatty liver diseases. [europepmc]
• Western Diet: Implications for Brain Function and Behavior. [europepmc]
• Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. [europepmc]
• The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. [europepmc]
• Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. [europepmc]
• Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. [europepmc]
• Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. [europepmc]
• The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. [europepmc]
• FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. [europepmc]
• Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). [europepmc]
• The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. [europepmc]
• Inflammation in obesity, diabetes, and related disorders. [europepmc]
• SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. [europepmc]
• Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. [europepmc]
• Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. [europepmc]
• Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. [europepmc]
• Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. [europepmc]
• METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. [europepmc]